Remarkably, tumor hypoxia, like EGFR expression, has been considered a predictor of tumor progression, resistance to radiotherapy and poor clinical outcome in patients, establishing a close interplay between the two [58,60]. The gene discussed is EGFR; the disease is neoplasm.